|
Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Depletion of the cholesterol esterifying enzyme acyl-Coenzyme A: cholesterol acyltransferase 2 (ACAT2, encoded by Soat2) protects mice from atherosclerosis, diet-induced hypercholesterolemia, and hepatic steatosis when fed high-cholesterol diet.
|
30630736 |
2019 |
|
Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Acyl-CoA: cholesterol acyltransferase-2 (ACAT2), an intracellular cholesterol esterification enzyme found only in the intestine and liver, has been demonstrated to be associated with hypercholesterolemia and atherosclerosis in mice.
|
16195894 |
2005 |
|
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Acyl-CoA: cholesterol acyltransferase-2 (ACAT2), an intracellular cholesterol esterification enzyme found only in the intestine and liver, has been demonstrated to be associated with hypercholesterolemia and atherosclerosis in mice.
|
16195894 |
2005 |
|
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Depletion of the cholesterol esterifying enzyme acyl-Coenzyme A: cholesterol acyltransferase 2 (ACAT2, encoded by Soat2) protects mice from atherosclerosis, diet-induced hypercholesterolemia, and hepatic steatosis when fed high-cholesterol diet.
|
30630736 |
2019 |
|
Hypercholesterolemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Acyl-CoA: cholesterol acyltransferase-2 (ACAT2), an intracellular cholesterol esterification enzyme found only in the intestine and liver, has been demonstrated to be associated with hypercholesterolemia and atherosclerosis in mice.
|
16195894 |
2005 |
|
Hypercholesterolemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The ACAT-2 and CYP7A1 mRNA expression were significantly decreased in HC diet supplemented with STG, while the mRNA levels of LDLR were markedly increased.
|
30937311 |
2019 |
|
Wolman Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Together, these data imply that SOAT2 inhibition, if applied concurrently with enzyme replacement therapy for LAL deficiency, may blunt the re-esterification of newly released unesterified cholesterol thereby improving clinical outcomes.
|
29246491 |
2018 |
|
Wolman Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
These studies illustrate how the severity of disease in a mouse model for CESD can be substantially ameliorated by elimination of SOAT2 function.
|
25450374 |
2014 |
|
Dyslipidemias
|
0.020 |
Biomarker
|
group |
BEFREE |
These new analogues are the most potent and selective SOAT2 inhibitors to be used as synthetic compounds and attractive seed compounds for the development of drug for dyslipidemia, including atherosclerotic disease and steatosis.
|
29323466 |
2018 |
|
Dyslipidemias
|
0.020 |
Biomarker
|
group |
BEFREE |
To investigate the relationship between ACAT-2 and dyslipidemia, we determined the structure of the human ACAT-2 gene and then studied the relationship between mutations of the ACAT-2 gene and dyslipidemia.
|
11325614 |
2001 |
|
Coronary Artery Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Rs28765985 of ACAT-2 gene are associated with CAD in Uygur subjects.
|
30696703 |
2019 |
|
Coronary Artery Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
To explore the possible impact of ACAT2 gene variants on CAD susceptibility and plasma lipid levels, three polymorphisms, 41A>G (Glu>Gly), 734C>T (Thr>Ile), and IVS4-57_58 ins48 bp (D/I), were genotyped in 809 CAD patients (CAD+) and 1,304 controls (CAD-) from three distinct Singaporean ethnic groups (1,228 Chinese, 367 Malays and 518 Indians).
|
16195894 |
2005 |
|
Steatohepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here we aimed to investigate whether depletion of Soat2 per se can reduce hepatic steatosis, also in the presence of very low levels of cholesterol in the diet, and the underlying mechanisms.
|
30630736 |
2019 |
|
Steatohepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
These new analogues are the most potent and selective SOAT2 inhibitors to be used as synthetic compounds and attractive seed compounds for the development of drug for dyslipidemia, including atherosclerotic disease and steatosis.
|
29323466 |
2018 |
|
Cardiovascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
In mouse models, previous work has demonstrated that either antisense oligonucleotide (ASO) or small molecule inhibitors of SOAT2 can effectively reduce CVD progression, and even promote regression of established CVD.
|
26729489 |
2016 |
|
Coronary Arteriosclerosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Acyl-CoA: cholesterol acyltransferase-2 gene polymorphisms and their association with plasma lipids and coronary artery disease risks.
|
16195894 |
2005 |
|
Coronary heart disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Acyl-CoA: cholesterol acyltransferase-2 gene polymorphisms and their association with plasma lipids and coronary artery disease risks.
|
16195894 |
2005 |
|
Fatty Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here we aimed to investigate whether depletion of Soat2 per se can reduce hepatic steatosis, also in the presence of very low levels of cholesterol in the diet, and the underlying mechanisms.
|
30630736 |
2019 |
|
Hyperlipidemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This study was carried out to clarify the relationship between ACAT-2 gene mutations and hyperlipidemia in humans.
|
12621162 |
2003 |
|
Liver diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The existence of a new class of potent and selective SOAT2 inhibitors provides an opportunity for exploring if suppression of this enzyme could potentially become an adjunctive therapy for liver disease in NPC1 deficiency.
|
29878847 |
2018 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Based on GO, KEGG, GenMAPP, BioCarta and disease databases, we determined AGR2-mediated lung adenocarcinoma metastasis through repression with cytoskeleton of MAST1; steroid metabolism of SOAT2; humoral immune response of POU2AF1; interferon alpha-inducible of IFI6; immunoglobulin of IGKC_3, CTA_246H3.1.
|
24960290 |
2014 |
|
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Genes associated with β-oxidation (peroxisome proliferator-activated receptor α, carnitine palmitoyltransferase 1A, and hydroxyacyl-CoA dehydrogenase), lipoprotein excretion (apolipoprotein B, microsomal triglyceride transfer protein, and acyl-CoA:cholesterol acyltransferase 2), fatty acid transport (fatty acid-binding protein), construction of triglycerides in the endoplasmic reticulum (acyl-CoA:diacylglycerol acyltransferase 1), and LD degradation/lipolysis (comparative gene identification-58, adipose triglyceride lipase) were significantly downregulated in neoplasms compared with non-tumor areas.
|
26513060 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Based on GO, KEGG, GenMAPP, BioCarta and disease databases, we determined AGR2-mediated lung adenocarcinoma metastasis through repression with cytoskeleton of MAST1; steroid metabolism of SOAT2; humoral immune response of POU2AF1; interferon alpha-inducible of IFI6; immunoglobulin of IGKC_3, CTA_246H3.1.
|
24960290 |
2014 |
|
Liver mass
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
In the chow-fed mice, NPC1:SOAT2 double knockouts, compared with their littermates lacking only NPC1, had 20% less liver mass, 28% lower hepatic UC concentrations, and plasma alanine aminotransferase and aspartate aminotransferase activities that were decreased by 48% and 36%, respectively. mRNA expression levels for several markers of inflammation were all significantly lower in the NPC1 mutants lacking SOAT2.
|
29878847 |
2018 |
|
Chronic Kidney Diseases
|
0.010 |
AlteredExpression
|
group |
BEFREE |
CKD also resulted in increased enzymatic activity of HMG-CoA reductase and ACAT2 together with decreased enzyme activity of lipase and LCAT.
|
31828139 |
2019 |